MX2020013206A - Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos. - Google Patents

Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos.

Info

Publication number
MX2020013206A
MX2020013206A MX2020013206A MX2020013206A MX2020013206A MX 2020013206 A MX2020013206 A MX 2020013206A MX 2020013206 A MX2020013206 A MX 2020013206A MX 2020013206 A MX2020013206 A MX 2020013206A MX 2020013206 A MX2020013206 A MX 2020013206A
Authority
MX
Mexico
Prior art keywords
fatty acid
gnrh
pharmaceutical composition
binding
same
Prior art date
Application number
MX2020013206A
Other languages
English (en)
Inventor
Dong Kyu Jin
Original Assignee
Novel Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novel Pharma Inc filed Critical Novel Pharma Inc
Publication of MX2020013206A publication Critical patent/MX2020013206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Abstract

Un aspecto de la presente descripción se refiere a un nuevo derivado de hormona liberadora de gonadotropina (GnRH) conjugado con ácido graso de acción prolongada y una composición farmacéutica que lo contiene. Se espera que un derivado de GnRH de la presente invención contribuya en gran medida, a través de una excelente biodisponibilidad, un aumento de la vida media en sangre y efectos terapéuticos notablemente altos sobre la enfermedad dependiente de hormonas sexuales, a la reducción de la frecuencia y la dosis de dosificación del fármaco y similares en el tratamiento de enfermedades dependientes de las hormonas sexuales. En particular, el derivado de GnRH puede superar las desventajas de las preparaciones de liberación sostenida de GnRH existentes, que tienen los efectos secundarios de sensación residual y dolor en el lugar de la inyección.
MX2020013206A 2019-03-26 2019-03-26 Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos. MX2020013206A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2019/003527 WO2020196946A1 (ko) 2019-03-26 2019-03-26 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
MX2020013206A true MX2020013206A (es) 2021-02-26

Family

ID=72611599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013206A MX2020013206A (es) 2019-03-26 2019-03-26 Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos.

Country Status (9)

Country Link
US (2) US20210030846A1 (es)
EP (1) EP3785734B1 (es)
JP (1) JP7066913B2 (es)
CN (1) CN112955181A (es)
AU (1) AU2019437315B2 (es)
CA (1) CA3102364A1 (es)
ES (1) ES2944511T3 (es)
MX (1) MX2020013206A (es)
WO (1) WO2020196946A1 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06122611A (ja) * 1992-10-12 1994-05-06 Seiwa Kasei:Kk 化粧品用配合剤
US6664369B1 (en) * 1994-08-10 2003-12-16 Creighton University GnRH analogues with antitumour effects and pharmaceutical compositions thereof
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
GB2344287A (en) * 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
US6297379B1 (en) 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
JP2001139422A (ja) * 1999-11-18 2001-05-22 Shiseido Co Ltd 乳化組成物
WO2001070227A1 (en) 2000-03-17 2001-09-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
WO2002076402A2 (en) * 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
WO2004012712A1 (en) * 2002-08-02 2004-02-12 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders, contraception, and hormone replacement
US6960337B2 (en) 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
AU2002368261A1 (en) 2002-10-02 2004-04-23 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
JP2007517042A (ja) * 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
WO2005116058A1 (en) 2004-05-27 2005-12-08 Curepeptide Ltd. Peptides useful for treating gnrh associated diseases
ES2791698T3 (es) 2006-12-18 2020-11-05 Takeda Pharmaceuticals Co Composición de liberación sostenida y método para producir la misma
PL2331075T3 (pl) 2008-08-29 2016-04-29 Genzyme Corp Formulacje peptydowe o kontrolowanym uwalnianiu
JP5674089B2 (ja) * 2010-03-25 2015-02-25 日油株式会社 毛髪化粧料
US9694051B2 (en) 2011-04-07 2017-07-04 The Board Of Trustees Of The Leland Stanford Junior University Long-acting peptide analogs
ES2613856T3 (es) 2012-02-28 2017-05-26 Sk Chemicals Co., Ltd. Antagonistas del receptor de la hormona liberadora de gonadotropina, método para su preparación y composición farmacéutica que comprende los mismos
AU2013305563B2 (en) * 2012-08-24 2018-09-27 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
JP6822962B2 (ja) * 2014-12-23 2021-01-27 カムルス エービー 制御放出製剤
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
RU2746566C2 (ru) 2017-09-27 2021-04-15 Новел Фарма Инк. КОНЪЮГИРОВАННОЕ С ПАЛЬМИТИНОВОЙ КИСЛОТОЙ ПРОИЗВОДНОЕ GnRH ПРОЛОНГИРОВАННОГО ДЕЙСТВИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕГО

Also Published As

Publication number Publication date
CN112955181A (zh) 2021-06-11
US20220054593A1 (en) 2022-02-24
US20210030846A1 (en) 2021-02-04
JP2021524496A (ja) 2021-09-13
JP7066913B2 (ja) 2022-05-13
ES2944511T3 (es) 2023-06-21
US11975048B2 (en) 2024-05-07
EP3785734B1 (en) 2023-04-12
WO2020196946A1 (ko) 2020-10-01
EP3785734A1 (en) 2021-03-03
AU2019437315B2 (en) 2022-10-06
CA3102364A1 (en) 2020-10-01
AU2019437315A1 (en) 2020-12-03
EP3785734A4 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2011013150A (es) Composicion farmaceutica para uso en oftalmologia medica y veterinaria.
MX345942B (es) Composiciones de tabletas que se desintegran oralmente que comprenden combinaciones de farmacos en dosis alta y baja.
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
MX2020002247A (es) Derivado de gnrh de conjugado a ácido palmítico de larga duración y composición farmacéutica que lo contiene.
Avanti et al. A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate
FI3383385T4 (fi) Melflufeeniannoskuureja syöpään
MX2020013206A (es) Derivados de gnrh conjugados con acidos grasos de accion prolongada y composiciones farmaceuticas que contienen los mismos.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
EA201992685A1 (ru) Раствор леводопы для инфузий
RU2015120055A (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
AR120290A1 (es) Una forma de dosificación parenteral estable de acetato de cetrorelix
ZA202308033B (en) Method and pharmaceutical combination for preventing cancer recurrence
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
RU2015111491A (ru) Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира
MX2021014349A (es) Metodo para tratar cancer con una forma de dosificacion oral de un inhibidor de receptores de estrogeno-alfa.
MX2022009081A (es) Absorcion celular.
TW200633722A (en) Complexes made using low solubility drugs
RU2010122438A (ru) Противовирусное средство для профилактики и лечения клещевого энцефалита